Advice
Following a resubmission.
Paricalcitol solution for injection (Zemplar®) is not recommended for use within NHS Scotland for the prevention and treatment of secondary hyperparathyroidism in patients with chronic renal failure undergoing haemodialysis.
The benefits and adverse effects of paricalcitol are similar to another vitamin D analogue with which it has been compared. The manufacturer did not present a sufficiently robust economic case to gain acceptance by SMC.
Download detailed advice60KB (PDF)
Medicine details
- Medicine name:
- paricalcitol 5 micrograms/ml and 10 micrograms/ml solution for injection (Zemplar)
- SMC ID:
- 288/06
- Indication:
- for the prevention and treatment of secondary hyperparathyroidism (SHPT) in patients with chronic renal failure undergoing haemodialysis
- Pharmaceutical company
- Abbott Laboratories
- BNF chapter
- Nutrition and blood
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 07 July 2008